Patient made presentation on Kallmann syndrome.

For me the psychological issues associated with Kallmann syndrome / CHH should have more recognition.

Hormone replacement therapy can help with most (but not all) of the physical symptoms and specialised gonadtropin therapy can help some patients achieve fertility.

However the fact patients miss out on both puberty and adolescence can leave patients with symptoms that last well into adulthood. The psychsocial impact of not developing correctly can leave some patients with poor body image and social confidence problems

Since Kallmann syndrome / CHH comes with a range of symptoms and severities it can affect individual patients differently. Interacting with patient groups to communicate with fellow patients can help patients learn more about their condition and hopefully form a positive outlook.

Rare Disease Day 2023. Kallmann syndrome introduction

Clinical Study for female Kallmann syndrome / CHH patients in the UK.

Endocrinologists at Imperial NHS Trust in the UK are planning a clinical study focused on Kisspeptin administration to Kallmann syndrome / CHH females under 35 years of age.

The study will be based at Charing Cross Hospital in London and will involve three separate day visits to the hospital. Food will be provided during the visit as well as travel costs and attendance payment.

Kisspeptin is a hormone that directly affects the hypothalamus and normally allows the correct release of GnRH and has the potential to be used in the treatment of Kallmann syndrome / CHH both for hormone replacement and for fertility treatments.

The study aims to find the best method of using Kisspeptin in the treatment of infertility in females.

For further information please contact:

Dr Bijal Patel.

bijal.patel@imperial.ac.uk